Center of Molecular Medicine Central European Institute of Technology Masaryk University Brno Czechia

Centre for Haemato Oncology Barts Cancer Institute Queen Mary University of London London United Kingdom

Department of Haemato Oncology Barts Health NHS Trust St Bartholomew's Hospital London United Kingdom

Department of Internal Medicine Hematology and Oncology University Hospital Brno Masaryk University Brno Czechia

Division of Chronic Lymphocytic Leukemia Department of Internal Medicine 3 Ulm University Ulm Germany

Ulm University Hospital Ulm Germany

Editorial on the Research Topic Biology and treatment of high-risk CLL PubMed

See more in PubMed

Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program (2010) 1:481–8. doi: 10.1182/asheducation-2010.1.481 PubMed DOI

Hallek M, BD C, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. . iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood (2018) 131:2745–60. doi: 10.1182/blood-2017-09-806398 PubMed DOI

Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. . High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood (2018) 132:892–902. doi: 10.1182/blood-2018-01-826008 PubMed DOI

Campo E, Cymbalista F, Ghia P, Jager U, Pospisilova S, Rosenquist R, et al. . TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica (2018) 103:1956–68. doi: 10.3324/haematol.2018.187583 PubMed DOI PMC